RecruitingPhase 2NCT05465174

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults

Sponsor

Sabine Mueller, MD, PhD

Enrollment

57 participants

Start Date

Sep 12, 2022

Study Type

INTERVENTIONAL

Conditions

Craniopharyngioma Craniopharyngioma, Child Recurrent Craniopharyngioma

Summary

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Eligibility

Min Age: 1 YearMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tovorafenib for people with craniopharyngioma, craniopharyngioma, child, and other related conditions. The study is currently recruiting participants at 20 locations. People eligible for this study include aged 1 Year to 39 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTovorafenib

Given orally

Locations(20)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Rady Children's Hospital/University of California, San Diego

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Florida

Gainesville, Florida, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Riley Hospital for Children at Indiana University Health

Indianapolis, Indiana, United States

John Hopkins University

Baltimore, Maryland, United States

Dana-Farber/Boston Children's Harvard Medical School

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Children's Minnesota

Minneapolis, Minnesota, United States

St. Louis Children's Hospital Washington University

St Louis, Missouri, United States

NYU Langone Health

New York, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

John Hunter Children's Hospital

New Lambton Heights, New South Wales, Australia

Royal Hobart Hospital

Hobart, Tasmania, Australia

Children's Cancer Centre, Monash Children's Hospital

Clayton, VIC 3168, Australia

Royal Children's Hospital, Childrens' Cancer Centre

Parkville, Victoria, Australia

Perth Children's Hospital

Nedlands, Western Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05465174

Related Trials

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery

NCT073161011 location

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

NCT071774821 location

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT062998912 locations

Long-Term Longitudinal QoL in Patients Undergoing EEA

NCT040879021 location

The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction

NCT068744263 locations